Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice

Abstract

SummaryThe long-awaited 2022 World Health Organization Classification of Haematolymphoid Tumours (WHO-5-HAEM) has finally been published as part of the IARC Blue Book series. This two-volume edition is significantly more comprehensive than its predecessors, reflecting the integration of extensive advancements in genetic and molecular understanding, alongside clinically relevant findings. This brief review will highlight the key changes in the classification of the most common B‑cell lymphoproliferative disorders, specifically follicular lymphomas and large B‑cell lymphomas (LBCL). It will also introduce new entities and summarize the most critical updates within these lymphoma categories.